Overall verdict
Neutral
5.0/10
1-year performance
+88.64%
Score breakdown
Up 88.6% over 1 year, 83% of the 52-week range.
Strongest: Valuation 6.4/10. Weakest: Profitability 0.0/10.
21 analysts, target +0.1% vs the price.
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans.
This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group.
The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Sarah London
Founded
1984
Employees
61 100
Revenue / employee
3.2M USD
Next earnings
October 27, 2026 (Q3 2026)
Institutional holders
- BlackRock, Inc.8.56%
- VANGUARD CAPITAL MANAGEMENT LLC6.50%
- AQR CAPITAL MANAGEMENT LLC5.92%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.62%
- STATE STREET CORP4.54%
- GEODE CAPITAL MANAGEMENT, LLC2.75%
- WELLINGTON MANAGEMENT GROUP LLP2.75%
- AMERIPRISE FINANCIAL INC2.57%
- Invesco Ltd.2.31%
- Other institutions59.29%
- Rest of the register0.19%
997 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
69.63 USD
52-week low
31.63 USD
1-year performance
88.64%
Rising
Year-to-date performance
50.75%
Rising
Drawdown
-9.02%
Mild pullback
Position in the 52-week range
83% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 3.1 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Centene | 170 819 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 3.1 times as much as the world ETF.
- Worst fall:-78 % between August 2022 and August 2025. 10,000 € placed at the top fell to 2 222 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Centene earned 2 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Centene: 170 819 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Gross margin 8.0%, the company loses 2.5% of its revenue, ROIC -12.2%, ROE -20.4%.
Net margin
-2.51%
Negative
Sector 1.68%|S&P 12.97%
Gross margin
7.97%
Low
Return on equity (ROE)
-20.41%
Negative
Sector 10.87%|S&P 16.52%
Return on invested capital (ROIC)
-12.21%
Negative
Free cash flow margin (FCF)
4.41%
High
Margin stability
2.2 pts
Steady
Revenue to net income
Growth
3.6/10Revenue up 9.9% over 1 year, 11.9% a year over 5.
Revenue (trailing 12 months)
203Md USD
Revenue growth (1y)
9.92%
Moderate
Revenue growth (3y)
34.75%
Solid
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
38.87%
Sharply revised up
Valuation
6.4/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 28.2x|S&P 23.0x
Forward P/E
16.5x
Cheap
EV / EBITDA
—
N/A (loss)
Sector 15.4x|S&P 14.5x
PEG
—
Sector 0.23|S&P 0.86
P/E vs its own 5-year history
among the 10% lowest valuations
Far cheaper than usual
Market cap
30.7Md USD
Financial strength
3.5/10Cash covers 150.0% of the debt, net debt/EBITDA 1.5x.
Net debt / EBITDA
1.5x
Stretched
Gearing (net debt / equity)
-35.51%
Net cash
Cash
24.2Md USD
Cash / market cap
78.75%
Very solid
Cash / total debt
149.96%
Net cash
Interest coverage
-8.6x
Stretched
Net debt
-8.0Md USD
Equity
22.7Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 61.92 USD
- MM2065.50
- MM5065.12
- MM20052.11
- RSI 1439.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+6.02%
200-day average slope, 3 months
+21.93%
50-day average slope, 1 month
+0.19%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.13 % per day
Volatility change
-21.66%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 3.84 (7) | 4.88 (21) | 196 023 (15) | 2 904 (6) | 1 862 (7) |
| 2027 | 4.15 (7) | 5.35 (21) | 192 839 (15) | 3 255 (6) | 2 048 (8) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.5 | 7.8 | 2.0Md USD | 28.1x | 6.0 % | 5.3 % | 15.5 % | -3.1x | 9.0 % | 20.2 % | ||
| 2 | SAUD3 | 7.4 | 6.5 | 8.0Md USD | 14.3x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.6 % | 5.3 % | ||
| 3 | UNH | 7.1 | 6.3 | 333Md USD | 23.9x | 3.1 % | 0.4 % | 8.4 % | 1.9x | 7.1 % | 7.1 % | ||
| 4 | HQY | 6.9 | 6.2 | 7.5Md USD | 32.6x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 6.5 % | -5.7 % | ||
| 5 | ELV | 6.6 | 5.7 | 86.4Md USD | 17.7x | 2.5 % | 1.4 % | 6.7 % | — | 7.3 % | 22.7 % | ||
| 6 | HUM | 5.6 | 4.3 | 45.0Md USD | 35.5x | 0.9 % | 26.2 % | 4.1 % | -1.9x | 4.3 % | 47.6 % | ||
| 7 | CNC | 5.0 | 3.5 | 30.7Md USD | Not meaningful (loss) | -2.5 % | 9.9 % | -12.2 % | 1.5x | 29.2 % | 88.6 % | ||
| 8 | CLOV | 4.8 | 3.8 | 2.4Md USD | Not meaningful (loss) | -0.7 % | 55.6 % | -5.1 % | 3.5x | 3.1 % | 38.3 % | ||
| 9 | MOH | 4.6 | 2.9 | 9.9Md USD | Not meaningful (loss) | -0.0 % | -4.8 % | -0.1 % | -20.7x | 2.7 % | 6.0 % |
